- Home
- RMTI vs TVRD Comparison
RMTI vs TVRD Comparison
Compare RMTI & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMTI | TVRD |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 34.1M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | RMTI | TVRD |
|---|---|---|
| Price | $0.91 | $3.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $2.50 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 233.4K | 39.3K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $101,489,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.38 | N/A |
| 52 Week Low | $0.78 | $3.50 |
| 52 Week High | $2.10 | $43.65 |
Technical Indicators
Market Signals| Indicator | RMTI | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 51.83 |
| Support Level | $0.80 | $3.81 |
| Resistance Level | $1.02 | $4.39 |
| Average True Range (ATR) | 0.05 | 0.24 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 33.89 | 67.61 |
Price Performance
Historical ComparisonAbout RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.